Ligand Pharmaceuticals (LGND) Interest Expenses (2010 - 2026)

Ligand Pharmaceuticals has disclosed Interest Expenses across 17 years of filings, most recently posting $1.7 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $1.7 million, up 101.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (up 48.84% YoY), and the FY2025 annual result was $4.7 million, up 55.25% from the prior year.
• Interest Expenses came in at $1.7 million for Q1 2026 at Ligand Pharmaceuticals, down from $1.8 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $1.8 million in Q4 2025 to a low of $1000.0 in Q3 2023.
• The 5-year median for Interest Expenses is $741000.0 (2024), against an average of $702941.2.
• Across the five-year window, Interest Expenses sank 99.7% in 2023 and jumped 74000.0% in 2024, its largest moves.
• Ligand Pharmaceuticals' Interest Expenses stood at $240000.0 in 2022, then slumped by 45.42% to $131000.0 in 2023, then soared by 574.05% to $883000.0 in 2024, then jumped by 102.15% to $1.8 million in 2025, then fell by 2.13% to $1.7 million in 2026.
• The last three Interest Expenses figures came in at $1.7 million (Q1 2026), $1.8 million (Q4 2025), and $910000.0 (Q3 2025), per Business Quant data.